Suzhou Ribo Life Science Co., Ltd. (Ticker: 6938 HK) is a Chinese biopharmaceutical company specializing in the research and development of oligonucleotide therapeutics, with a primary focus on small interfering RNA (siRNA) drugs. Founded in 2007, the company develops innovative treatments for cardiovascular, metabolic, renal, and liver diseases. Its core product, RBD4059, is an FXI-targeting siRNA drug designed to treat thrombotic diseases and is currently in Phase 2 clinical trials.

Ribo Life plans to list on the Hong Kong Exchange on January 9, 2026. The company is offering approximately 27.49 million H-shares at a fixed price of HKD 57.97 per share. This IPO is expected to raise HKD 1.59 billion (USD 204.69 million), valuing the company at approximately USD 1.20 billion. According to the prospectus, Ribo Life plans to allocate the vast majority of the IPO proceeds toward R&D and product capacity expansion for its pipeline assets, with the remaining funds set aside for working capital and strategic acquisitions. The offering is joint-sponsored by CICC and Citigroup.